Immunoglobulins in Norway - organization and challenges Brre Fevang - PowerPoint PPT Presentation

Regional Health Authorities • Northern • Western Population 250’ Population 1,1 mill 18’ employees 25’ employees • Central • South-Eastern Population 740’ Population 2,9 mill 14’ employees 78’ employees Immunoglobulins in Norway - organization and challenges Børre Fevang Section of Clinical Immunology and Infectious Diseases

Current supply of immunglobulins • Hospital use • All intravenous immunoglobulins • National procurement with long-term contracts with wholesaler, currently Panzyga • Stockpile of critical medication required • Stable supply • Use at home • All subcutaneous immunoglobulins • No national procurement • No stockpile required • Intermittent shortage of several subcutanous brands

Challenges 800 000 700 000 600 000 500 000 Gram 400 000 300 000 200 000 100 000 0 EST-2018 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 IVIG SCIG • General increase in the use of immunoglobulins in Norway • Increasing use of subcutanous products as immunmodulating therapy – switch from IVIG to SCIG • Shortage of alternative intravenous products ( Kiovig and Privigen) if severe side effect of Panzyga